Takhzyro Safely Prevents HAE Attacks Over Long Term, Extension Study Shows
News
Takeda’s Takhzyro (lanadelumab) continues to safely prevent and reduce the frequency of swelling attacks in people with hereditary angioedema (HAE), according to 2.5 years of data from the HELP ... Read more